Sangamo Therapeutics Inc (SGMO) — Cash Flow Reinvestment Rate

Latest as of September 2024: 0.03x

Sangamo Therapeutics Inc (SGMO) has a Cash Flow Reinvestment Rate of 0.03x as of September 2024, reinvesting $348.00K (capex $115.00K plus investments $233.00K) from operating cash flow of $11.76 Million. See SGMO free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

0.03x
(Capex + Investments) / Operating CF

Total Reinvested

$348.00K
Capex + Investments

Operating Cash Flow

$11.76 Million
USD

Capital Expenditures

$115.00K
USD

Sangamo Therapeutics Inc Cash Flow Reinvestment Rate (2017–2020)

Historical reinvestment intensity for Sangamo Therapeutics Inc across 3 annual periods. For the full cash flow conversion analysis, see Sangamo Therapeutics Inc (SGMO) cash conversion ratio.

Annual Cash Flow Reinvestment Rate for Sangamo Therapeutics Inc (2017–2020)

Year-by-year capital reinvestment analysis for Sangamo Therapeutics Inc. See financial agility of Sangamo Therapeutics Inc to measure the company's free cash flow as a share of total liabilities.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2020 1.59x $270.92 Million $169.88 Million $14.71 Million ▼ -42.2%
2018 2.76x $102.46 Million $37.15 Million $43.06 Million ▼ -60.2%
2017 6.92x $77.40 Million $11.18 Million $3.75 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow